/

Sociétés

Bi

Non vérifié

Biocytogen

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueSantéScience

11 communiqués de presse

Voir tous les communiqués de presse

15/06/2026

Industrie

Vétérinaire

Science

Politique Intérieure

Médecine - Divers

Biotechnologie

Santé

Industrie pharmaceutique

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Source

Émetteur

1.00

0

15/06/2026

Industrie

Vétérinaire

Science

Politique Intérieure

Médecine - Divers

Biotechnologie

Santé

Industrie pharmaceutique

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery

Source

Émetteur

1.00

0

26/05/2026

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

Source

Émetteur

1.00

0

26/05/2026

Technique

Science

Médecine - Divers

Biotechnologie

Santé

Industrie pharmaceutique

Santé Publique

Industrie

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

Source

Émetteur

1.00

0

28/02/2026

Industrie

Santé

Santé Publique

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Source

Émetteur

1.00

0

09/01/2026

Marché du travail

Industrie

Oncologie

Santé

Science

Industrie pharmaceutique

Biotechnologie

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

Source

Émetteur

1.00

0

17/06/2025

Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing

Source

Émetteur

1.00

0

09/01/2025

Marché du travail

Industrie

Science

Équipement médical et sanitaire

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

Santé

Oncologie

Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment

Source

Émetteur

1.00

0

07/01/2025

Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors

Source

Émetteur

1.00

0

07/01/2025

Marché du travail

Industrie

Oncologie

Santé

Science

Industrie pharmaceutique

Biotechnologie

Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0